SOURCE: Press Ventures

October 14, 2013 17:00 ET

Press Ventures Prepares Submission for CLO-D Biosafety System With National Institute of Hygiene (NIH) and National Institute of Public Health (NIPH) Testing

WARSAW, POLAND--(Marketwired - Oct 14, 2013) - Press Ventures Inc. (OTCQB: PVEN) ("Press Ventures" or the "Company"), through its wholly-owned Polish subsidiary Biosafety Systems, Inc. Sp z o.o. ("BSI"), is pleased to announce that it will be submitting its patented natural Cedar Leaf Oil Diffusion ("CLO-D") bacteria and virus biosafety system to the National Institute of Hygiene (NIH) and National Institute of Public Health (NIPH) for testing in Poland. The tests are designed to determine the types of microorganisms in the CLO. If the independent laboratory analysis determines that the CLO contains no harmful pathogen microorganisms, a Statement of Certification will be issued. The estimated time frame for the completion of the testing is 4 to 6 weeks from the date of submission.

"An endorsement from such a highly regarded European Union public health institution would send a clear signal to our potential customers and other biosafety market players that the CLO-D system and solutions developed and marketed by BSI can take a lead role in the fight against harmful airborne containments that plague human and animal habitats," stated Mr. Edward Denkiewicz, Press Ventures CEO. "Following a positive outcome of the NIH - NIPH testing, BSI expects to sell CLO-D biosafety systems in all sectors of the biosafety market, including agricultural, commercial, and residential."

Founded in 1918, The National Institute of Hygiene (NIH) is the oldest public heath institution in Poland. The mission of the National Institute of Hygiene - National Institute of Public Health is to protect the health of the population through actions taken in the field of public health, including research and training. This refers to the monitoring of biological, chemical and physical risk factors in food, water and air as well as diseases and infections control. At present, the scope of scientific interests of the NIH - NIPH encompasses issues connected with the prevention of infectious diseases and socially important non-infectious diseases, the monitoring of the population's health situation, the improvement of hygiene and sanitary conditions as well as the safety of natural environment.

About Press Ventures

Press Ventures holds the worldwide rights to the patented Cedar Leaf Oil Diffusion ("CLO-D") technology for the use of natural products to kill bacteria, mold, and viruses in buildings. The patented CLO-D technology has been shown to be capable of killing many deadly bacterial and viral substances such as anthrax and H1N1 in buildings while they are still occupied. The CLO-D technology has been laboratory and field tested and the Company believes that use of the technology can provide a marked improvement in air quality and eliminate many of the most dangerous airborne bacteria, viruses, and pollutants. For additional information about CLO-D technology and Press Ventures, please visit

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, submission of CLO-D product to NIH and NIPH for testing, potential future sales of CLO-D product, and capability of the Company's technology and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at

Contact Information